Switch Obstacles In Europe Threaten OTC Industry Growth – GSK Exec
This article was originally published in The Tan Sheet
Executive Summary
European perceptions that OTC status increases safety risks hinders switch applications, GSK exec Scarlett-Smith contends. He argues OTC buyers are health conscious, adverse events are not isolated to OTCs and despite the centralized switch process, members retain decentralized OTC policies.
You may also be interested in...
European Countries Urged To Boost OTC Profile In Health Care Systems
EU Health Commissioner John Dalli expects the region’s growing health care budgets and economic crisis to lead governments to restructure and impose more responsibility on consumers for health care costs. A self-medication working group launched in France will look at easing Rx-to-OTC switches.
OTC Growth Will Not Find A Friend In Europe’s Financial Upheaval
As economic conditions tighten in Europe, former Pfizer exec Cavan Redmond expects consumers will spend less on OTCs while increasing their scrutiny of products and prices. Difficult economic conditions sharpen the constant necessity for OTC firms generate growth, he says.
European Countries Urged To Boost OTC Profile In Health Care Systems
EU Health Commissioner John Dalli expects the region’s growing health care budgets and economic crisis to lead governments to restructure and impose more responsibility on consumers for health care costs. A self-medication working group launched in France will look at easing Rx-to-OTC switches.